Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Harvard Bioscience Inc. (HBIO:NASDAQ), powered by AI.
Harvard Bioscience Inc. is currently trading at $5.95. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Harvard Bioscience Inc. on Alpha Lenz.
Harvard Bioscience Inc.'s P/E ratio is -4.7.
“Harvard Bioscience Inc. trades at a P/E of -4.7 (undervalued) with modest ROE of -147.1%.”
Ask for details →Harvard Bioscience Inc. is a developer, manufacturer, and distributor of scientific instruments, consumables, and systems. The company's primary function is to facilitate advanced research, aiding life science professionals in their pursuits of cutting-edge scientific inquiries. Harvard Bioscience offers an extensive array of products, including apparatus for cell analysis, microfluidics, drug discovery, and bio-processing. These advanced devices are crucial for laboratories within sectors such as biotechnology, pharmaceuticals, and academic research institutions, helping to drive innovation and discovery in medical and life sciences. Headquartered in Holliston, Massachusetts, Harvard Bioscience holds a pivotal role in supplying essential tools and technologies that empower scientists and researchers worldwide. By continually evolving its product offerings, the company addresses the needs of an ever-changing market and supports the progression of scientific advancements that can impact global health outcomes. This makes Harvard Bioscience an integral component of the scientific research infrastructure, contributing significantly to technological and methodological developments in its field.
“Harvard Bioscience Inc. trades at a P/E of -4.7 (undervalued) with modest ROE of -147.1%.”
Ask for details →Harvard Bioscience Inc. (ticker: HBIO) is a company listed on NASDAQ in the Healthcare sector (Medical Instruments & Supplies). It has approximately 330 employees. Market cap is $264M.
The current price is $5.95 with a P/E ratio of -4.66x and P/B of 19.23x.
ROE is -147.13% and operating margin is 0.12%. Annual revenue is $87M.